The global Alzheimer’s disease diagnostics market size was estimated at USD 8.33 billion in 2024 and is projected to reach USD 15.57 billion by 2030, growing at a CAGR of 11.03% from 2025 to 2030. The market is being driven by several key factors, including the increasing prevalence of Alzheimer’s disease (AD), the growing use of biomarkers in disease diagnostics, the rising adoption of personalized healthcare solutions, and ongoing technological advancements in medical imaging. These developments are collectively fueling the demand for more efficient and accurate Alzheimer’s diagnostics.

In addition, increasing government investments and extensive R&D studies are further supporting market growth. As the global population ages, the need for early and accurate diagnostic tools continues to rise. According to the 2024 Alzheimer’s Association, the risk of dementia increases with age, and the number of Americans affected by Alzheimer’s disease is expected to grow significantly. By 2050, the population aged 65 and older is projected to reach 82 million, up from 58 million in 2022. Moreover, by 2030, all baby boomers (born between 1946 and 1964) will be 65 years or older, making them the age group most susceptible to Alzheimer’s dementia.

Significant progress has also been made in the development of novel therapeutic drugs that target the underlying causes of Alzheimer’s disease. For example, in January 2023, the U.S. FDA granted accelerated approval to lecanemab, a treatment co-developed by Eisai Co., Ltd. and Biogen Inc. Eisai also sought manufacturing and marketing approval in Japan, where the drug received a priority review from the Ministry of Health, Labour and Welfare (MHLW). However, the effective use and distribution of such therapies require technologies capable of detecting amyloid-beta (Aβ) accumulation in the brain. Traditional diagnostic methods, such as cerebrospinal fluid (CSF) testing and amyloid PET scans, are both invasive and costly, which has intensified the demand for simpler, less invasive, and more accessible diagnostic approaches.

Key Market Trends & Insights:

• The North America Alzheimer’s disease diagnostics industry held the largest share of 47.63% in 2024, reflecting the region’s advanced healthcare infrastructure, high awareness of neurodegenerative diseases, and widespread adoption of innovative diagnostic technologies.

• Within North America, the U.S. Alzheimer’s disease diagnostics industry is expected to experience substantial growth during the forecast period, driven by increasing prevalence of Alzheimer’s disease, rising government funding for research, and growing demand for early and accurate diagnostic tools.

• By type, the diagnostic segment dominated the market in 2024, capturing the largest share of 53.55%. This dominance is due to the extensive use of diagnostic tools and tests in clinical practice, research, and pharmaceutical applications to detect and monitor Alzheimer’s disease progression.

• By end-use, the academic and research institutes segment led the market in 2024, holding the largest share of 48.07%. The high share reflects the critical role that universities, research centers, and specialized institutes play in developing and validating novel diagnostic techniques, studying disease mechanisms, and supporting clinical trials.

• By diagnostic technique, imaging techniques accounted for the largest revenue share of 41.12% in 2024, driven by the increasing use of PET scans, MRI, and other imaging technologies to detect amyloid-beta accumulation, brain atrophy, and other disease biomarkers that enable early diagnosis and treatment planning.

Order a free sample PDF of the Alzheimers Disease Diagnostics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 8.33 Billion

• 2030 Projected Market Size: USD 15.57 Billion

• CAGR (2025-2030): 11.03%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Some of the key players operating in the Alzheimer’s disease diagnostics market include Quest Diagnostics Incorporated, Abbott, F. Hoffmann-La Roche Ltd., Eli Lilly, Bio-Rad Laboratories, Inc., Eisai Co Ltd., and several others. The market is characterized by high competitiveness, with a large number of manufacturers collectively accounting for the majority of the market share.

To maintain and strengthen their positions in this competitive landscape, companies are increasingly focusing on new product developments, mergers and acquisitions, and strategic collaborations. These initiatives are aimed at enhancing technological capabilities, expanding product portfolios, and increasing global reach, while also addressing the growing demand for early and accurate diagnostic solutions for Alzheimer’s disease.

Key Players

• Quest Diagnostics

• Labcorb

• C2N diagnostics

• FujireBio

• Hoffmann-La Roche

• Quanterix

• Sysmex

• Lantheus

• Siemens Healthineers

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The Alzheimer’s disease diagnostics market is positioned for significant growth in the coming years. Its expansion is driven by rising prevalence of dementia worldwide, increased use of biomarkers and advanced imaging technologies, greater emphasis on early and accurate diagnosis, and growing R&D investment. The evolving diagnostic landscape — including non invasive biomarker tests and enhanced neuroimaging — is expected to broaden access and improve early detection. As diagnostics become more precise and accessible, this will support better disease management, treatment planning, and research efforts globally.